Long-Term Effectiveness and Safety of Isatuximab in Combination with Pomalidomide and Dexamethasone in a Japanese Patient with Refractory Multiple Myeloma and 1q21 Amplification: A Case Report
Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory multiple myeloma (RRMM), including those with gain or amplification of chromosome 1...
Saved in:
| Main Authors: | Takanori Yoshioka, Yasuhisa Sando, Kazutaka Sunami |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000543347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
by: Sargam Rachit Vohra, et al.
Published: (2025-07-01) -
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01) -
Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01) -
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
by: Enrica Antonia Martino, et al.
Published: (2025-03-01) -
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
by: Aaron S. Rosenberg, et al.
Published: (2025-08-01)